Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Inge M W Verberk und 20 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Net…. Hauptthemen laut MEDLINE: Biomarkers, tau Proteins, Neurofilament Proteins, Glial Fibrillary Acidic Protein. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Stichting Steun Alzheimercentrum Amsterdam, Innovative Medicines Initiatives 3TR.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P‐)tau181, amyloid‐beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS We measured the plasma biomarkers with Simoa ( n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS P‐tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre‐dementia stages, AUC = 87%–89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%–76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand‐alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION Our multimarker blood test interpretation tool is ready for testing in real‐world clinical dementia settings. Highlights We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P‐tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
- Translational Artificial Intelligence Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health, Amsterdam, The Netherlands.
- Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain.
- Memory Centre, Division of Geriatrics and Rehabilitation, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland.
- Laboratory of Biological Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Förderung
- Instituto de Salud Carlos III
- Stichting Steun Alzheimercentrum Amsterdam
- Innovative Medicines Initiatives 3TR
- NIA NIH HHS
- Marató TV3
- Generalitat de Catalunya
- Noaber Foundation
- Fondo Europeo de Desarrollo Regional, Unión Europea, "Una manera de hacer Europa" National Institutes of Health
Zitieren
APA
Verberk, I. M. W., Jutte, J., Kingma, M. Y., Vigneswaran, S., Gouda, M. M. T. E. E., van Engelen, M. P., Alcolea, D., Arranz, J., Fortea, J., Lleó, A., Chevalier, C., Marizzoni, M., van de Giessen, E. M., Lemstra, A. W., Pijnenburg, Y. A. L., van der Flier, W. M., den Braber, A., Wilson, D., Schut, M. C., …, & Teunissen, C. E. (2024). Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14088
Vancouver
Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, et al. Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14088
BibTeX
@article{Verberk2024,
author = {Verberk, Inge M W and Jutte, Jolien and Kingma, Maurice Y and Vigneswaran, Sinthujah and Gouda, Mariam M T E E and van Engelen, Marie-Paule and Alcolea, Daniel and Arranz, Javier and Fortea, Juan and Lleó, Alberto and Chevalier, Claire and Marizzoni, Moira and van de Giessen, Elsmarieke M and Lemstra, Afina W and Pijnenburg, Yolande A L and van der Flier, Wiesje M and den Braber, Anouk and Wilson, David and Schut, Martijn C and van Harten, Argonde C and Teunissen, Charlotte E},
title = {Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14088}
}
EUVIMED